Teva Pharmaceutical Industries Limited (TEVA) Earnings Call Transcript
January 28, 2026
Earnings Call Speaker Segments
Much appreciated, Alex. Hello, everyone, and welcome this morning and afternoon. We're glad you could be with us for the call covering our fourth quarter. Prior to handing things to Richard Francis, our CEO, I'd like to note for all of you that forward-looking statements will be part of what we discuss today. Everything we say reflects only the present day, and we take on no duty to revise such statements later on. Should you have questions regarding those forward-looking statements, please look at the relevant portions of our SEC Forms 10-K and 10-Q. So, Richard Francis.
Thanks, Chris. Hello everyone, whether you're with us this morning or this afternoon — glad to have each of you on the call. Dr. Eric Hughes, who leads R&D and serves as our Chief Medical Officer, is here with me today, and he'll walk you through some promising pipeline updates. Following him, my CFO Eli Kalif will go over the fourth quarter and full year results. As is my habit, I'll start with the Pivot to Growth strategy and where we stand after 3 years. As you know, there are 4 pillars serving as our base. First, delivering on our growth engines — the numbers, I think, demonstrate that we continue to generate strong momentum from our innovative lineup of AUSTEDO, UZEDY and AJOVY, plus we're making steady headway on innovation, which means stepping up innovation. You'll note that we submitted olanzapine last year, wrapped up enrollment for the DARI study, which is the dual-action rescue inhaler, and kicked off our Phase III trial for duvakitug in UC and CD. Second comes the sustained generics powerhouse, where we've made nice progress. Getting this business back to stability is what we set out to do, and we've done it. At this point, we're seeing encouraging growth emerge from our biosimilars portfolio, and I'll touch on that briefly, and then concentrate the business. The whole point here is making sure our capital is deployed where it can generate the strongest returns. We're going to walk you through where things stand with our transformation program, which is designed to produce $700 million in net savings by 2027. During '25 we moved ahead very well, and we expect to hit the 2/3 mark by the close of this year, 2026. So let's turn to the results themselves. These results make me happy. To help you get your bearings on this slide, the numbers on the left side factor in the Sanofi milestones, while the ones on the right leave them out; so let's start with revenues. Revenues rose 5%, reaching $17.3 billion. EBITDA was up 12%, hitting $5.3 billion. Our earnings per share climbed 19%, reaching $2.93, while free cash flow rose 16% to $2.4 billion. The ratio of net debt to EBITDA is currently 2.5x, and as you're aware, we're targeting 2x by 2027. So we're making solid progress toward that goal. Now, here's a slide I've actually presented for the past 12 quarters, illustrating our return to growth — which formed part of the Pivot to Growth strategy we introduced back in 2023. As you can see, we've achieved this in consecutive periods, including Q4, when growth came in at 11%. That figure did benefit from the Sanofi milestone. Excluding it, we'd have been marginally negative, at 1%. However, consider the 3-year window; across that span, the outcomes are quite strong, and keep in mind that sales had fallen for several consecutive years. During 2023, we achieved 4% growth in the business, followed by 11% in '24 and 2% in the most recent year, which the slide makes clear puts us squarely on pace to hit our mid-single digit CAGR target. Let's now examine some specifics driving these favorable outcomes. The following slide shows that innovative performance stands out as a major area of growth. For the full year, AUSTEDO, UZEDY, and AJOVY together totaled $3.1 billion, representing roughly a 35% increase — truly outstanding results. I'm happy to report that during the fourth quarter, our innovative portfolio—which you can see on the screen—went past $1 billion. To give you a little more granularity: AUSTEDO rose 34%, reaching $2.26 billion. UZEDY climbed 63%, hitting $191 million. AJOVY continues to deliver, gaining 30% to $673 million. Results in our generics segment were unchanged, and it's important to mention that Japan is not included in these figures. I've spoken at length about our transformation from a company focused solely on generics into a biopharma business. These numbers, I believe, make it evident that we've completed that shift. So now the real question becomes how far we can continue to push this innovative portfolio along with the pipeline feeding into it. Let me turn to some additional specifics. I'd like to give you some context on AUSTEDO. As you can see, AUSTEDO delivered a very impressive quarter 4, reaching $725 million, which represents 40% growth for that quarter; and on a full-year basis, it hit $2.2 billion, a 35% increase. And that came from solid underlying momentum. TRx, as you can see, is 10%, and milligram volume rose 19%. What's fueling this is a combination of new patients coming in and improved adherence; it's worth noting that AUSTEDO XR now makes up 60% of new patients. These are really strong numbers. In Q4, the figures were boosted by some inventory building at year-end and beneficial gross-to-net adjustments — Eli will go into more specifics on that. Strip those factors out, though, and we still delivered 20% growth in Q4. So again, this product's fundamental momentum remains very powerful. Given that, our guidance for 2026 comes in at $2.4 billion to $2.55 billion. Worth pointing out: reaching the top of that range would put us at $2.5 billion one year earlier than planned. We'll get into the specifics of what's helping and hurting within that range a little later on. Turning now to UZEDY: it delivered yet another robust quarter at $55 million, which is a 28% increase, and across the entire year it climbed an impressive 63% to reach $191 million. TRx volume posted a striking 123% gain compared with the prior year. Something else worth highlighting — more than 83% of incoming NBRx came from individuals either transitioning off oral therapies or with no prior treatment history, which demonstrates that UZEDY is expanding the long-acting injectable segment instead of simply taking share. One more notable fact regarding UZEDY: among competing products in its class, it holds the fastest growth rate. With that kind of trajectory, our guidance reflects it. As you can see, we're guiding to $250 million to $280 million for 2026. Turning now to AJOVY. AJOVY also posted a solid quarter, rising 43% year-on-year to $211 million. For the full year, that's $673 million, a 30% increase. So again, for a product that's relatively mature, the growth is genuinely strong. AJOVY remains the #1 preventative anti-CGRP injectable at the top U.S. headache centers, and it holds the lead in 30 markets across Europe and international. This ongoing growth, I believe, comes from our commercial excellence, our capacity to keep gaining market share, to navigate the pricing and payer landscape in the U.S., and to keep expanding into new geographies. Because of that momentum, our outlook is now set at $750 million to $790 million. Turning to what's in development: we've already gone over the items currently being sold and how well they're doing, yet what's coming down the line is genuinely thrilling. I'd like to touch on this myself, even knowing Eric plans to address it as well.
One thing I always highlight about this slide is that every product we plan to launch has a potential worth more than $1 billion. The markets we're entering are large, and we're getting into them soon. When you add it all up, the combined portfolio might reach over $10 billion in peak sales. There's a new addition here that many of you probably haven't seen: later this year, we'll be disclosing 2 additional indications for duvakitug, which again shows this is a pipeline in a product. Now let's move on to our generics business. When it comes to our generics business, our objective was to restore stability, and we've done that. Versus 2024, the generics business was flat in 2025. One point I make all the time is that you have to look at this business over multiple years, because some years bring more launches than others. That's just the nature of how it works. As you can see here, our 2-year CAGR is 6%. For 2025, though, the U.S. grew at 2%, international markets, 1% and Europe declined 2%. Now we keep seeing solid performance from our biosimilars business, and I think I'll turn to that now to walk you through it. Looking back at how we got into biosimilars three years ago, the progress has been remarkable. At this point, we have 10 products being sold around the world, with 6 more set to enter the market by the close of 2027, and then an additional 10 will begin their launches starting in 2028 and continuing afterward. Those are some pretty striking figures. Our aim was to create a portfolio that leads on a global scale, and that's exactly what we've accomplished — as I see it, we now hold the industry's second biggest biosimilars portfolio, plus we've brought more biosimilars to market than anyone else since 2020. Thanks to all of this, we remain firmly on course to expand our biosimilars business by $400 million come 2027. To wrap things up, based on several figures we've already discussed, we're on a solid path toward achieving the 2027 guidance. As for the CAGR I mentioned, we're at 6% right now. Regarding operating margin, more specifics will follow, but given how well our innovative portfolio has performed, we have strong confidence in reaching 30%. On net debt to EBITDA, the target is 2x while we're currently sitting at 2.5x, and cash to earnings stands at 80% — Eli will give you further details on that. With that said, I'll turn things over to Eric to discuss our exciting pipeline.
Appreciate that, Richard. I'll begin with the slide Richard quickly walked through. A key point regarding this pipeline: it contains 3 Phase III programs along with 2 Phase II programs that are growing rapidly. The market potential here is substantial, as Richard noted. Yet what matters even more is the unmet medical need that we feel proud about and what we might be able to address. Lastly, I want to mention that our planning for submissions spanned over 5 years. So we take real pride in having reversed the fortunes of this innovative pipeline and advanced it so rapidly. But first, let me put a spotlight on olanzapine LAI. We filed on December 9, and we're looking at a submission to the EU sometime in Q2 of this year. With olanzapine LAI, we've shown it can meet a medical need in schizophrenia that isn't currently being addressed — the safety and efficacy data are strong — and our goal is to discuss this with the health authorities and, if all goes well, get that approval by the close of this year. That's an exciting thing to look forward to. Turning to our DARI program, the dual-action rescue inhaler, we're very proud that target enrollment for the study was finished at the end of 2025. In fact, we'll continue enrolling patients in order to accelerate the later portion of the study. What stands out most about that study population — and it's among the toughest pieces — is that kids, teens, and grown-up patients are all included. So my view is that having a dry powder inhaler that stands apart, plus the chance to get adolescents and pediatrics into the label, makes this program truly distinctive, and it tackles a big unmet need in asthma. Now shifting to duvakitug, which is a brand-new biologic class still being developed and quite thrilling. Twelve months back, we shared highly encouraging Phase II results for ulcerative colitis as well as Crohn's disease, with strong figures in each and a good dose response. We're really looking forward to the maintenance data coming out in the first half of this year. What matters most with that maintenance data is that it should demonstrate, we hope, how long the response lasts — and that's exactly what patients with ulcerative colitis and Crohn's disease require. Both are chronic conditions in which people often stop responding to their advanced therapies and require something additional. So long-term durability is the key thing. As a quick recap, this covers 58 weeks of exposure, evaluating two different doses administered subcutaneously every 4 weeks. Richard also noted that our Phase III initiatives with Sanofi—SUNSCAPE and STARSCAPE—kicked off exactly as scheduled, and we're speeding them up, performing strongly, plus we expect additional indications within this year. Turning next to anti-IL-15: at JPMorgan we shared exciting news that Royalty Pharma is funding our vitiligo work through a Phase II/III study. That gives us genuinely strong external validation for this program, which we view as a highly differentiated offering targeting multiple unmet medical needs. Beginning with vitiligo: systemic treatments are necessary in that setting, and data ought to arrive in the opening six months of this year. Also, with regard to celiac disease, a second proof-of-concept study is now enrolling, and it relies on a biopsy endpoint; results should arrive during the latter six months of this year. In addition, alopecia areata, atopic dermatitis, and eosinophilic esophagitis each stand out as possible targets for this very important cytokine. Now, regarding emrusolmin: what has really struck me is the sheer speed at which people have been signing up for this trial. This is a Phase II study that looks at key endpoints connected to a major unmet medical need. I frequently note that people who have this disease confront an average survival of 6 to 10 years after being diagnosed. That is what makes it such a substantial unmet medical need. We're working intensely to make sure this trial doesn't merely fill up quickly — our goal is to enroll beyond the target, so this Phase II effort comes out as clean and as strong as possible, truly putting us in position to perhaps capitalize on a faster approval route. Prior to reaching my last slide, I want to recognize the AJOVY group over at Teva. What they've done in producing migraine findings has been exceptional, and watching the New England Journal of Medicine publish our innovation this month brings us real satisfaction. The team did outstanding work, and because of that we got approval for the first and only CGRP antagonist with a pediatric indication for episodic migraine — so I couldn't be prouder, excellent job, and credit goes to the team. One more thing I'd like to mention, something that makes us very proud. 2026 looks extremely promising, with lots of milestones coming throughout R&D. As I mentioned, duvakitug data lands in the first half. On the anti-IL-15 side, vitiligo results arrive in the first half, while celiac findings come during the back half of 2026. We'll be looking out for the final event in DARI's asthma exacerbation trial before the year closes, which would wrap up the Phase III study. Toward the close of this year, Emrusolmin is set to undergo a futility analysis, and at the same time we're speeding up and expanding the number of participants in that Phase II trial. On top of that, we fully expect olanzapine LAI to secure approval as the year wraps up, and we'll also be reviewing initial human results for our anti-PD-1 IL-2. So this is truly an electrifying year filled with catalysts. We're eager for each of these milestones, and now I'll pass it to Eli Kalif.
Appreciate that, Eric, and greetings to all of you, whether you're joining in the morning or the afternoon. I'm going to take you through how we performed financially in 2025, zeroing in on Q4, and after that I'll share our outlook for 2026. Let me start with a handful of important points that demonstrate just how steady our execution was throughout 2025. To kick things off, we delivered strong numbers in Q4 as well as for the entire year, driven yet again by our innovative portfolio that's expanding rapidly and is simultaneously reshaping our margin profile in a significant way; this represented our third consecutive year of growth since the Pivot to Growth strategy was introduced. Also, the strength of our balance sheet continues to build — we've reduced net debt to about $13 billion, and our net debt-to-EBITDA ratio now stands at 2.5x. That leaves us clearly on the road to hitting our 2x goal and reaching investment-grade ratings. On top of that, we've made substantial progress with our transformation programs, realizing $70 million of the savings we planned for 2025, staying on course to achieve roughly $700 million in savings by 2027, and meeting our 30% non-GAAP operating margin targets. Last, with how we performed in 2025 and what we expect in 2026, we're in a strong position to achieve our long-term financial targets for 2030. Let's now turn to Slide 28. Prior to getting into the numbers, let me note that in Q4 of 2025, Teva launched a Phase III study for the UC and Crohn's indication within our duvakitug program. Per our collaboration deal with Sanofi, this development milestone brought us $500 million during that fourth quarter; that sum boosted our revenue as well as our free cash flow by $500 million, and it also helped our adjusted EBITDA by roughly $410 million. As I go through this presentation, the figures I'll cover for both the quarter and the entire year of 2025 will be presented without factoring in those milestone payments. In addition to those payments, I'm removing any impact from the Japan business venture that we sold off on March 31, 2025, so you get a more apples-to-apples view of how our financial results compare; with that, let's begin with how we did in Q4 on a GAAP basis. Revenue for the quarter was roughly $4.2 billion, which represents a 2% increase in U.S. dollars, or a 1% decline in local currency versus the same period last year. AUSTEDO, AJOVY and UZEDY — our key innovative products — maintained solid momentum, with each one landing at or above the full-year guidance we provided. Offsetting this robust expansion in our innovative portfolio along with steady generics was a drop in proceeds from selling certain product rights relative to Q4 2024. When you factor in the development milestone payments, GAAP net income came to $480 million, with EPS at $0.41. Turning to how we did on a non-GAAP basis: gross margin improved 80 basis points compared with a year earlier, reaching 56.2%, which brought the full year figure to 54.7% — comfortably above the upper limit of the guidance we had provided. That gain came primarily from faster-than-anticipated expansion in our key innovative products, with AUSTEDO leading the way. Non-GAAP operating margin, meanwhile, declined about 120 basis points relative to the prior year, settling at 26.7%, which mostly reflects the planned step-up in OpEx spending intended to support growth in our innovative portfolio. All told, we closed the quarter with non-GAAP earnings per share of $0.68, down from $0.70 in Q4 2024. Non-GAAP adjustments totaled $649 million in Q4. That figure encompassed a $77.3 million impairment charge, tied mostly to a European manufacturing facility. Free cash flow came to about $800 million in Q4 and $1.9 billion across the full year, which landed at the upper end of our guidance range, leaving out the development milestones tied to duvakitug. Turning to Slide 29. Our Teva transformation programs are driving substantial progress toward delivering targeted savings of roughly $700 million by 2027, achieved through clearly defined and planned efforts. During 2025, we captured $70 million of savings right out of the gate, which reflects real momentum and strong execution. We continue to anticipate that roughly two-thirds of the overall savings goal will be reached by the time 2026 ends. Alongside the ongoing shift in our portfolio toward innovative products that deliver high growth and high margins, these transformation initiatives give us a clear route to achieve our 30% operating margin target by 2027, all while we continue putting money into the business to drive long-term growth. I'll now turn to what we expect for 2026. Like I mentioned before, 2025 was a year where we made solid headway with our Pivot to Growth strategy — revenue went up, profits and margin both improved, we invested in our innovative products and pipeline, and we made meaningful strides toward reaching investment-grade ratings. Looking at 2026, our attention remains on keeping that momentum going and carrying out the accelerate growth portion of our strategy. Starting with what we expect for revenue in 2026: we're projecting full year revenue in the range of $16.4 billion to $16.8 billion. On a normal base, that works out to somewhere between roughly 1% growth and a 2% decline compared with 2025, once you set aside the $500 million in development milestone payments as well as the $75 million that the Japan business venture contributed in 2025. This outlook for revenue is consistent with the guidance we gave before. It shows the momentum we're still seeing from newer products like AUSTEDO, AJOVY, and UZEDY, plus modest growth in the low single digits from our global generics segment. Together, that should mostly counter about $1.1 billion of revenue pressure in 2026 tied to generic Revlimid. For non-GAAP gross margin in 2026, we're looking at somewhere between 54.5% and 55.5%, which would be another step up from a solid 2025, helped again by the favorable mix shift across our portfolio and savings generated by the transformation initiatives we're running. So, as we've said before, we anticipate both non-GAAP operating income and adjusted EBITDA will rise in absolute dollars and also as a share of revenue versus 2025. We expect operating costs to come in between 27% and 28% of revenue, and the cost savings from the transformation program ought to have a bigger effect during the back half of the year. When we look at 2026, finance expenses ought to be roughly $800 million, below the figure we recorded for 2025, and that number captures both the reduced debt on our balance sheet and the ongoing deleveraging. As for the non-GAAP tax rate, we're anticipating a range of 16% to 19%, slightly higher than 2025, because last year benefited from integration plans tied to IP along with the recognition of certain U.S. tax attributes. That brings us to an anticipated non-GAAP EPS range of $2.57 to $2.77. Free cash flow for 2026 should land somewhere between $2 billion and $2.4 billion, which shows a solid continued strengthening in how we convert cash and lines up with the targets we've set for the long term. Then, finally, I want to give you some direction on how we're thinking about the quarterly cadence in 2026; revenue should build up gradually as the year goes on, with the second half of 2026 coming in a bit above the first half. We see Q1 as light, and that's mostly for these reasons: First, U.S. generics revenue will be down year over year, largely because roughly $300 million of generic Revlimid revenue from Q1 of 2025 is dropping off. Second, with AUSTEDO, in Q4 of 2025, on top of how strongly AUSTEDO performed underneath, we got a lift from a year-end inventory build plus a onetime gross to net of about $100 million.
For AUSTEDO, we anticipate robust year-over-year expansion in the first quarter of 2026, though we also anticipate that Q1 revenue will show the sequential effect of those onetime benefits. Additionally, we anticipate that AUSTEDO revenue in Q4 '26 could decline year-over-year, driven by differing purchasing patterns and pricing conditions prior to the IRA taking effect in January 2027. Our non-GAAP margins should also increase gradually throughout the year, consistent with the revenue trajectory and savings from the transformation programs currently underway. Those onetime revenue dynamics I mentioned will further affect gross margin in Q1, beyond the usual seasonality between Q4 and Q1. Free cash flow should likewise build over the year; on the next slide, I want to call attention to the robust free cash flow trajectory we are pursuing. Three primary elements will keep generating incremental free cash flow, taking us from roughly $1.9 billion in 2025, excluding duvakitug milestone payments, to over $3.5 billion by 2030. First, our innovative portfolio is uniquely positioned to keep growing strongly, which drives higher margins and free cash flow. Furthermore, we remain on track to deliver $700 million in savings from transformation programs by 2027. We won't stop there, and we will keep pushing Teva's modernization past 2027. Second, we keep reinforcing our balance sheet via working capital and CapEx optimization. And finally, we keep deleveraging, with a reduction in our debt anticipated to bring lower finance expenses of roughly 50% by 2030, and we anticipate a decrease in our legal payments over time. Now to the next slide on capital allocation. Our capital allocation strategy centers on advancing our Pivot to Growth strategy; that means continuing to invest in our key growth drivers and our world-class innovative pipeline. We are also making substantial progress toward our goal of 2x net debt-to-EBITDA and investment-grade credit ratings; the major credit rating agencies have consistently acknowledged this progress, including the recent upgrade by S&P and an improved outlook by Moody's; given the progress we have made, I expect us to reach these goals in the not-too-distant future, which also puts us in a strong position to carefully consider additional ways of returning capital to our shareholders. Finally, before I wrap up my review of our 2025 performance, I want to restate our long-term targets; we are clearly on the path to becoming a leading innovative biopharma company. With our expanding innovative mix, several key pipeline developments this year and our free cash flow trajectory, we are confident in the direction we are headed to hit our 2027 and 2030 financial targets. With that, I will now hand it back to Richard for his closing remarks.
Appreciate it, Eli, and thanks as well, Eric. The next slide I'll move to is the same one Eric put up, though I believe it deserves another look. For Teva, this has been a truly thrilling year when it comes to milestones across our innovative portfolio; on this slide we've got 7 of them. So that's something I'm very proud of, and I'm very proud of what the team has accomplished. Naturally, we've got some promising data involving vitiligo, anti-IL-15, and celiac disease. Later in the year comes the olanzapine launch. We've got the duvakitug maintenance data as well as the futility analysis, which might speed up how quickly we can bring emrusolmin to market for this extremely serious disease. So there's ample opportunity ahead to keep pushing this transition toward becoming a world-class biopharma company. Once more, congratulations to the R&D team for advancing this so rapidly. In only 3 years, we moved this pipeline forward at record pace. It's thanks to this pipeline, and thanks to the sustained strong results in our innovative portfolio that I brought up earlier and Eli brought up too, that we feel confident in the chance to keep growing Teva's top and bottom line, and that's why we view it as an appealing investment opportunity. Since, as you can see on this slide, we not only have considerable headroom for AUSTEDO and AJOVY, we also have the LAI franchise, with UZEDY doing well, while olanzapine is set to be added to it this year. I pointed out how many biosimilars are going to launch across the coming years. And looking ahead, that pipeline — the readouts I just referenced — will begin delivering results. So we can sustain this momentum as we move forward. Turning to my last slide, just to wrap up. Our growth story carries on; we've had 3 straight years of growth. We have a 6% CAGR. Our innovative brands are expanding at double digit, and there's headroom for them to keep expanding. We have near-term milestone readouts, 7 in '26; plus we have a steady outlook for our generics business, and we stay focused on speeding up our Pivot to Growth journey. With that said, I'll turn things over for questions. Thank you.
Thanks, Richard. Alex, before you start taking questions, I’d like to remind everyone on the call to please keep it to one question and one follow-up. If there’s time left, we’ll gladly take more questions from you if you rejoin the queue. Thank you.
Two things I want to cover — AUSTEDO first, then UZEDY. The guide's color coding helps, but I'm hoping you can unpack the various tailwinds and headwinds that will shape AUSTEDO's 2026 performance. Specifically, what can you tell us about net pricing trends, and what have you assumed once we strip out both the fourth-quarter gross-to-net benefit and any stocking contribution? How should we frame your net pricing expectations as the year progresses? Beyond that, what are your underlying assumptions for volume expansion, especially when measured per milligram? That wraps up my first topic. My UZEDY question is essentially the same. Clearly, we're seeing substantial increases in volume, yet at the same time there's meaningful government involvement, especially with Medicaid. So what's the right way to approach net pricing in that context? And which assumptions are reflected in your UZEDY guidance?
David, I appreciate the questions. I'll start with AUSTEDO. The first thing worth emphasizing is how encouraged we are by the momentum — both in TRx expansion, in XR uptake, and in the ongoing rise in milligrams, which came in at 19%, as you noticed. The underlying picture is quite robust, and there's a major chance ahead for us to keep expanding on a TRx basis given how many patients have yet to receive treatment. That basic strength is clear. On the question of pricing, as we said during last year, our goal has consistently been securing both value and access. With that in mind, we've approached this year with real care. Sure, competition has increased — there's no denying that. But our approach has been highly disciplined, and because of that, I believe we've held onto both the value and the access. So in my view, there's nothing there that stands out as particularly meaningful. When it comes to AUSTEDO, the key point is this: we wrapped up 2025 with genuinely impressive growth, not just in top line results but also in milligrams and TRx. And like I mentioned, once you remove the impact of that inventory build, the gross-to-net picture still reflects very strong performance. So when you step back and look at how we're doing across this range, I'd say the range we have is quite strong. There's an assumption baked in that some destocking could happen in Q4 of 2026, though we'll have to wait and see how it actually unfolds. One more point on AUSTEDO, just to make things a bit clearer: when you look at the range we provided and strip out the inventory build from Q4, the brand's growth comes out to somewhere between 11% and 18%. That's quite robust growth off a much larger base, which I think addresses what you were asking about AUSTEDO. Regarding UZEDY, as you've witnessed, the expansion has been extremely robust—TRx growth is genuinely impressive, and there's ongoing, quite favorable evolution in how this market behaves, which speaks to the product's caliber. Turning to what you asked, though, I believe it's consistently crucial to recognize that both Medicaid and Medicare are in play for us. That's the blend we carry. And clearly, one of those two is more lucrative than the other; the way that combination shakes out has been incorporated into our guidance and our range. Still, we observe ongoing momentum for this product, especially when you note how elevated the TRx figure is. So my view is that this product has a great deal of excitement surrounding it, yet the pricing fundamentals are what matter. We've built those in, and ultimately it boils down to those 2 channels. Appreciate the question, David.
Nice work on the quarter. First off, I'd like to know where you believe the biggest gap sits between the parts of your pipeline you're most enthusiastic about and what the Street isn't factoring in regarding those products? Then, a second thing — following up on AUSTEDO, how ought we to approach modeling 2027 given IRA plus whatever other forces push or pull here?
All right. Appreciate those questions. On the pipeline, I might split this somewhat with Eric. What — listen, I'll never claim anyone is overlooking something, since everyone here has deep experience in this industry. Still, I do believe our pipeline has advanced quite rapidly — consider the speed angle; perhaps that took people by surprise. That said, the caliber of our antibodies, the caliber of anti-TL1, the caliber of duvakitug, I believe, will prove itself in the data. So most likely, what I'd expect is that as we flip over those cards and the data comes in, Teva will then be acknowledged for having a world-class pipeline. Yet it's perhaps somewhat startling for people to witness just how good the pipeline is that has surfaced in so brief a period; but maybe I'll pass it to Eric for his perspective on that.
Absolutely. Richard, Louise, thanks for raising that. I want to underscore a point Richard made. The pace at which this innovative portfolio has been moved forward has, frankly, taken people aback; we've brought online an entirely new biologic, duvakitug, likely the top product in its class for TL1A. Olanzapine LAI has been launched — or, with luck, will be launched before this year ends. Still, don't simply trust what we say. Independent confirmation has come in for 4 out of these 5 programs. Royalty Pharma supplied funding for olanzapine LAI. Sanofi, recognizing its worth, took on duvakitug as a partner. Abingworth gave recognition to the DARI program. Royalty Pharma has, once more, recently given recognition to the anti-IL-15 program. And regarding emrusolmin too, a Fast Track designation plus an orphan designation have come our way. So throughout the whole innovative pipeline, we've sped things up — perhaps, in the eyes of investors, somewhat unexpectedly. Yet simply examine the outside validation our pipeline has drawn and factor that into how you assess value.
Thanks, Eric. Now, regarding your last question — I believe it was essentially seeking some kind of outlook for AUSTEDO in 2027, and I'm not going to provide that. Clearly, we've stated that we intend to reach $2.5 billion for AUSTEDO in 2027. That commitment hasn't changed at all. As you can see from the range we released today, there's a possibility we could reach $2.5 billion during 2026. So we'll need to watch how things develop. What matters most with AUSTEDO, I believe, is continuing to remind everyone that 85% of individuals living with tardive dyskinesia remain untreated; therefore, the chance to keep assisting these patients, to bring them in and provide them with treatment, represents, I think, a major growth driver for AUSTEDO. We also have the efforts underway to ensure patients can gain the benefits of AUSTEDO XR. And as you can observe, 60% of new patients transition to AUSTEDO XR, and we recognize that this supports compliance and adherence, which naturally in turn boosts value. So I think there are plenty of value drivers behind AUSTEDO, but I truly don't wish to be pulled into giving 2027 guidance right now. What I hope people will recognize is the strong momentum we have coming out of '25. We're bringing that forward into '26, and perhaps we'll discuss '27 around this time next year.
Ash, appreciate the question. I'll split this with Eric once more.
Regarding how we fund R&D, I believe the underlying ask was: what's your approach to paying for this, and do these partnerships mean you're handing over value? The way we see it, we're sitting on a sizable late-stage pipeline. There are plenty of chances for us to generate substantial value. In my experience and my view, when your pipeline is strong, the priority becomes getting it to patients faster so they can benefit and so revenue starts flowing. That's why we're pushing a large pipeline ahead at real speed here. Now, what does that do to the economics? Honestly, it doesn't move the economics in any significant manner, for two reasons. First, every one of these brands will exceed $1 billion. A number of them will be multi-billion brands. Second, and this is a point I think gets overlooked about Teva, we begin from a gross margin position that looks very different from many other biopharma companies. So each innovative product we bring to market reshapes our gross margin, and that reshapes our capacity to generate EBITDA, EPS, and cash flow. So like I said, these arrangements aren't surrendering value in any broad sense. Yet even specifically for Teva, they don't, given the starting point of this journey. Another point I want to emphasize: we're bringing so many products to market across such a compressed timeframe, and that's where our attention sits. We could potentially launch 4 products within 5 years, and we'll keep announcing additional indications. So the pipeline is really about ensuring rapid movement to market. But we are absolutely not giving away value. I'd argue we're speeding up value thanks to how fast we're moving. Now, on your question about the TL1A maintenance data and what we expect — I'll let Eric take that, then I'll wrap up.
Absolutely. Yes. Thank you, Ash, for asking about our expectations from the TL1A maintenance data. Let me begin with the story we've shared concerning duvakitug at Teva. We began by stating that our in vitro research showed we possessed the most potent antibody, the most selective antibody, and the one likely to have the fewest antidrug antibodies. In our Phase II study, I believe we observed roughly 3% to 5%. With that in hand, we moved into our Phase II program, which we carried out extremely well and quickly. We then generated the highest reported figures for both ulcerative colitis and Crohn's disease across 2 studies that were very well-controlled and well-run. So the in vitro findings translated into an excellent Phase II outcome. If you apply that same thinking to what we expect in maintenance — considering we have the most potent, most selective option with the lowest antidrug antibodies, and that we can run the trial effectively — my hope is that once we lock the database, we'll see strong results. So I'm optimistic about it. Hopefully that proves correct, but we'll find out what the data tells us.
Appreciate that, Eric. We hold to the position that ours is the top TL1A — and that’s what we believe.
Eli, one thing I missed — could you discuss the 2026 guidance, specifically how gross margin is expected to look relative to the OpEx spend ratio? My understanding is that the latter falls in the 27% to 28% range that you folks have referenced historically, but I simply wanted that verified from a modeling standpoint. Then, for my follow-up on vitiligo, I was hoping to get a better sense of what this upcoming Phase Ib will deliver. Will VASI75 scores come through for the entire evaluable period? Do you anticipate that most of these 30-plus patients will remain through the whole evaluable period? I'm just curious how robust that data will be.
Thanks, Jason. Thanks for the question. So I'll hand it to you, Eli, on the gross margin.
Jason, I appreciate you raising that. Regarding gross margin, when we strip out the 2 milestone payments, we closed the year at 54.7%; for 2026, we expect to land somewhere between 54.5% and 55.5%. As for OpEx, two main forces are at play. To start, as I noted during my prepared remarks, we'll see somewhat elevated OpEx — still within 27% to 28% during the first half compared with the second half, purely due to how revenue unfolds across the year. Beyond that, there's an additional factor within OpEx: we anticipate a greater decrease in our G&A, and in fact moving that decrease across R&D and sales and marketing, which lets us hold it steady within the 27% to 28% range. So that particular item is unchanged from what we previously communicated.
Right. And what I would put on top of that, Jason, is that gross margin makes for a genuinely thrilling narrative for us, since, as you can observe, while we keep expanding our innovative portfolio and keep bringing products to market, that gross margin is simply going to continue climbing. The only open question is by how much, yet climb it will, given that we are transforming our portfolio so dramatically. Now, when it comes to the vitiligo data, I will pass things to Eric.
Absolutely, and thanks for asking that, Jason. So what we'll be sharing during the first half of 2026 comes from a study with a single arm, focused on vitiligo patients. Roughly 38 people will be enrolled altogether. The endpoints we'll use are the standard, well-established ones for this area — facial VASI along with total VASI — which means it can be compared without difficulty against other therapies on the market. That brings up something important: treatment options for vitiligo remain quite limited right now. Only one has gotten approval, and it's a topical covering just 10% of the body. What's currently in development, meanwhile, is exactly what's needed — systemic approaches that address not merely the face but the whole body, going beyond that 10%. So a really encouraging aspect of our anti-IL-15 program in vitiligo, when we discuss it, is its potential to work as a single subcutaneous injection given once every 3 months — a quarterly shot, possibly, for treating a disease that's systemic. That's something we're eager about. I believe you'll receive data allowing us to line it up against both approved and in-development treatments elsewhere.
Let's stay with IL-15 for a moment; regarding how long development takes in vitiligo, could you explain more precisely what is required for that 2031 pathway as opposed to '34? And I'm wondering, does a comparable opening exist in celiac as well? Then, if I may squeeze in one very brief item, turning back to AUSTEDO. I believe you mentioned an approximate $100 million gain in 4Q, and it seems that sits between rebate and inventory. When we consider destocking in 1Q, could you make clear what portion of that was inventory and what portion was this rebate reversal?
Appreciate the question, Chris. Eric, would you like to begin with the anti-IL-15, vitiligo and celiac?
Absolutely, and I appreciate the question regarding IL-15. To begin with, IL-15 is a crucial cytokine across a variety of indications, as I noted earlier. Our efforts are focused on vitiligo and celiac. I feel enthusiastic about the possibilities in alopecia areata, atopic dermatitis, and eosinophilic esophagitis as well. Each of these is compelling and significant for this cytokine. When it comes to vitiligo, our excitement is especially high since this is a program we can advance rapidly; there are precedents for the regulatory endpoint; and it's an endpoint that's simple to assess. You can observe the outcomes. That makes things somewhat simpler. Plus, there's an unmet medical need in this area. Systemic therapies are needed, as I said earlier. So at Teva, we're thinking creatively, and we're speeding up this program through a smart approach involving a Phase II and Phase III study that allows us to collaborate very swiftly with the regulators. Thus, the prospect of a subcutaneous injection given once every quarter is something we find very exciting.
Appreciate that, Eric. Now regarding what Chris asked about AUSTEDO, the way I'd frame that $100 million is that nearly all of it — nearly all of it — was essentially the inventory. Which is exactly why, clearly, we feel quite confident about 2026 in our figures. So I hope that answers it, Chris.
When I examine the variance from consensus for this quarter, it appears to come from sales and marketing once I exclude the one-time milestone effect; and it happens to strike me that this is likely the largest sales and marketing expenditure quarter we've observed across roughly the past 3 years. So I'm wondering what explains that, particularly since it's occurring while the transformation is in progress, that's my first point. Second, regarding '26 guidance, would it be accurate to state that the Royalty Pharma $75 million payment for Phase IIb is included inside the EBITDA? And are there additional milestones incorporated into the EBITDA guidance too, from TL1A or anything else? And last, on vitiligo, OPZELURA clearly hasn't performed all that well, though as Eric noted, it has limited coverage. But would it be accurate to say that with scores such as OPZELURA displaying around 30% facial VASI75, you'd want to be seeing meaningfully higher given Royalty Pharma is fully enthusiastic and they're not funding celiac, only vitiligo. I'm just curious about your broader view on expectations.
Umer, thank you for the questions. You packed a few into that single question there. So I appreciate it; regarding sales and marketing and the OpEx, I'll pass that over to Eli to address.
All right, Umer. So to begin with, regarding your question on Royalty Pharma, of that $75 million, the way we see it, it will actually be spread across '26 and '27, with one-third of the $75 million occurring in '26. For the '26 year, it's more backloaded. And that's the only item embedded in there. I wouldn't say we have any other assumptions within our EBITDA tied to TL1A milestones or anything of that nature. When it comes to sales and marketing, if you were to strip out the higher revenue stemming from the milestone, you'd arrive at roughly 15.4% on sales and marketing; however, moving into next year, we're going to see that figure actually at 16%, and why is that? Because we continue investing in our growth engine, which is AUSTEDO, and in fact, as we head into next year, we're building investment into our olanzapine launch. So we're going to see that figure rise. But taken altogether, the entire bucket is going to be, from a dollar standpoint, really rather flat, and also from a percentage standpoint, given that you'll see our transformation program impacting the G&A, as I told Jason, and that's essentially a reduction in G&A that's going to be divided between the R&D investment and the sales and marketing.
Appreciate that, Eli. Before I pass things along to Eric, let me tack on one more point. When you look at what we're projecting for this year — that EBITDA figure — I believe it demonstrates what our initiatives have delivered, what pushing our innovative portfolio forward has accomplished, and the reality that our transformation effort amounted to $700 million in net savings once we'd funded our growth drivers. As a result, we've positioned ourselves to keep advancing that innovative portfolio, which supports that EBITDA number, while our efficiency efforts simultaneously contribute to it as well. So we feel quite good and quite proud that our EBITDA begins with a 5, which matters, in my view; even so, we stay very conscious of how we deploy our money and where our capital gets directed. On the subject of vitiligo, I'll turn that over to Eric.
I appreciate the question, Umer. Regarding the information we currently have on the topical product available in the market and whatever is being worked on in development, my goal is always to be competitive on whichever endpoint you're referring to. So with any luck, once we lock the database and obtain those results, we'll be able to demonstrate that we stack up well against what's on the market. That said, let's keep our attention on what patients actually require. What they require is a systemic therapy that can be administered conveniently. So comparing it to a topical applied to 10% of your body is nearly inappropriate. Even so, we certainly hope to be competitive.
Nice work on the advances. I'd like to zero in on biosimilars. What's the timing for launches and how do you expect profitability to look, especially considering U.S. channel and PBM factors? Also, what needs to happen for you to go after the 10 additional products past 2028? You've looked at or talked about revisiting BD in this area before; so which approach — in-licensing, co-development, or tuck-ins — matches your current leverage and margin profile? And with the latest policy shifts, has that threshold moved?
Appreciate the questions. On biosimilars, yes, it's an exciting time. The speed at which we've assembled the number two portfolio — and our ongoing expansion of it — really shows how much emphasis we placed on this area. To offer some detail: right now, 10 are already on the market, and another 6 are set to arrive by '27. Most of those 6 will span both the U.S. and Europe, which matters a great deal since we've never really established any meaningful footprint in Europe. That region, we recognize, brings faster adoption, greater predictability, and returns that are quite clear. So that's something we're enthusiastic about. Just to give you a few examples, there's biosimilar Prolia, biosimilar Xgeva, biosimilar Simponi, biosimilar Eylea, and biosimilar Xolair. So a great deal is coming our way in those markets, and the majority of them are involved in both. Simponi, I believe, is the one that's only in the U.S. Now, you brought up the 10. And the way you asked made it sound as though 10 was a target we'd set. No — we have 10. They're already in our pipeline; we're simply going to keep adding to it. So we have 10, which is the reason I said we can begin launching from '28 onward, but we keep adding to that number. And regarding the last piece of what you asked—how does pursuing this via partnerships affect gross margin? Well, we'll keep going down the partnership route, and provided we've got the right partner, it remains appealing on the gross margin side. For our generics business, it's still meaningfully additive. That's the approach we take. And you'll likely see a few deals start to land as early as the first half of this year, since we're already expanding this portfolio past '26. And that brings me to my last point on this: we've got a steady stream of biosimilars arriving, which will be a real boost for growing our generics operation in both Europe and the U.S. down the line. Appreciate the question.
Les, could you repeat your BD question, please?
Basically, I was hoping to understand whether there's room for you to go somewhat further through BD in that area, whether anything might be out there through partnerships you've had before, and really, what's your approach in that space?
Apologies — is your question about biosimilars?
Right, that matches my thinking. As I see it, Les, I've already covered that point. Partnerships will keep being part of what we do. With several of them, we already enjoy solid, sizable alliances with businesses where we see room to grow — be it mAbxience or be it Samsung. So expansion is what we're focused on there. Beyond that, other firms have come to us wanting to serve as their partner, clearly because our U.S. results have been strong. Ours is the Humira biosimilar growing quicker than any other. Our American operation is expanding at a very rapid clip right now, so I believe that's what people are noticing. Still, yes, partnerships will be the route, and most of it will come that way.
If I could, I have a couple of things. First off, a broader question regarding R&D. At Teva, what's your philosophy when it comes to R&D? And I suppose, from the data readouts coming this year, how much derisking do you believe we'll see around the R&D platform? I'm also wondering what else might be lined up for 2027 as you move some of these newer drugs ahead? Then secondly, just a question about BD. As you shift into being a novel biopharma company, I'm curious whether your BD philosophy has shifted in any way, and whether Teva might have interest in making acquisitions in, let's say, the classic biotech space instead of what has historically been spec pharma.
Thanks, Dennis. Appreciate the question. I'll pair up with Eric on that, and perhaps begin with the philosophy of R&D, or maybe what we'd call the strategy.
Yeah. No, thanks for asking that, Dennis — it's a really key question. I'd say the way we think about things and the way Teva runs comes down to being completely hard-nosed about data. What we have, above all, is a Phase III and Phase II pipeline that carries relatively low risk. Emrusolmin, I'd say, sits at the bottom when it comes to the odds of succeeding. But if you look across our programs, we lean on science that's already understood, and we put it together so that it gets done well and fast, with regulators signing off. And all of that rests on data alone. Something I've come to see — and something I've managed to pull off while at Teva — is that once data shows up, we change direction and keep going with it. In earlier stops in my career, I was never in a position to do that. So moving quickly and getting things done, guided by data, alongside this approach of using established science and lower-risk assets — that's the path we'll take going forward. At this point, I'd say that's built into each of our programs.
Appreciate that, Eric. Now, regarding your following question about BD as we shift toward becoming a biopharma-focused organization: first off, I value that you acknowledge this transition on our part. In my view, the pivot has already happened. Regardless, we'll continue demonstrating it through the pipeline as new assets emerge. That said, yes, we are actively evaluating BD opportunities, and we believe our commercial team is a real powerhouse. The performance of AUSTEDO, UZEDY, and AJOVY speaks to that. So our goal is to strengthen that team further. Having said that, as Eric pointed out, our pipeline is genuinely exciting, so the organic growth heading our way is quite strong. That means we aren't in a position of needing BD desperately. It's not mandatory for us. That said, when an opportunity aligns with our therapeutic areas—CNS neurology and immunology—it becomes highly synergistic and makes tremendous sense, so we're quite active on that front. What's notable is that over the past year to 18 months, the number of inbound approaches has risen considerably. I believe that's due to these parties viewing Teva as a partner—both on the R&D side, where the pace at which we advance things through the clinic generates excitement, and, more importantly, because of our commercial strength and expertise, plus the attention we devote to assets once we hold one. If it's in development, we concentrate and push it forward rapidly; if it's on the market, we concentrate and truly generate sales. So ideally, we'll have things to share down the road. Still, our capital allocation remains highly disciplined. When it's the right asset, at the right moment, for the right price, we'll absolutely proceed. But given the pipeline flowing through, we can maintain that discipline firmly, and we will—because returning to that fourth pillar of the Pivot to Growth strategy, it concerns disciplined capital allocation, ensuring solid returns across the short, medium, and long term while generating shareholder value. So I appreciate the question, Dennis. With that, I believe that was the last one. We ran slightly long, though I think we began a couple of minutes behind schedule. So thank you for your questions and your interest in Teva, and I look forward to continuing this discussion later with our Q1 results. Thank you.
Thank you all for joining today's call. You may now disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teva Pharmaceutical Industries Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Teva Pharmaceutical Industries Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.